Prognostic value of clinical, laboratory and molecular predictors in the formation of personalized approaches to breast cancer treatment.

Authors

  • A. V. Phokhach State institution “Dnipropetrovsk medical academy of the Ministry of Health of Ukraine”, Ukraine
  • M. H. Elhajj State institution “Dnipropetrovsk medical academy of the Ministry of Health of Ukraine”, Ukraine
  • I. N. Bondarenko State institution “Dnipropetrovsk medical academy of the Ministry of Health of Ukraine”, Ukraine
  • V. F. Zavizion State institution “Dnipropetrovsk medical academy of the Ministry of Health of Ukraine”, Ukraine
  • V. A. Hurtovyi Dnipropetrovsk City Multidisciplinary Clinical Hospital №4, Ukraine

DOI:

https://doi.org/10.26641/1997-9665.2016.2.53-60

Keywords:

breast cancer, tumor response, molecular subtypes, polychemotherapy

Abstract

Background. The death rate from breast cancer in the past 10 years has increased steadily and has won first place in frequency among women. Despite advances in modern oncofarmakology, there is a heterogeneous tumor response to treatment between different patients. The objectives of our study were to evaluate the relationship between tumor response to systemic therapy and general and histological characteristics of patient’s tumors, including molecular subtypes of breast cancer, identify patterns between antropometric parameters of patients, comorbidities, and tumor response to the treatment; to study the effect of hematological, blood biochemical parameters on the results of the treatment of breast cancer. Methods. Molecular subtypes of breast cancer were established among 7521 patients, their changebility or stability in 67. Overall survival data was available for 491 patients with metastatic disease, peculiarities of development of metastases based on RECIST 1.1. criteria - 306. Retrospectively reviewed medical records of 110 patients with inoperable breast cancer (breast cancer) who received systemic therapy for the standard scheme. In the course of treatment were studied indicators such as: medical history of patients, life history, hematology, blood biochemistry, the results of primary and repeated histological and immunohistochemical studies of tumors, determination of molecular subtypes of breast cancer. Results. The distribution of the molecular subtypes of patients were as follows: A luminal - 69% luminal B - 9%, HER-2 / neu-positive - 7%, triple negative - 15%. Accounting factor Ki-67 (≥14%) led to an increase in the frequency of luminal B subtype from 9% to 19% by reducing the luminal A. In 44.8% of patients it was noted a change of molecular subtypes. Targeted therapy (Herceptin) in these patients allowed to overcome unfavorable prognostic background - results in median survival from them (41,3±4,5 months) were higher than in the group without Herceptin (27,4±3,4 months) and higher than the HER-2 / neu-negative patients (38,1±3,0 months). The value of coefficient Spearman rank correlation to tumor response and the factor of menopause, age, general condition of the patient were - 0.174; -0.222; -0.250 (P <0.05), in accordance. The status of regional nodes N and tumor response have the correlation coefficient: - 0,265; (P <0.05), the status of the primary tumor T and metastases M - 0.107; and -0.071 (p> 0.05), in accordance. In the presence of neutropenia at 1 week after treatment it has been revealed significantly better tumor response to treatment - the correlation coefficient: 0.204 (p <0.05). Conclusion. Molecular subtypes detection had shown that HER-2/neu-positive and tripple negative breast cancer demonstrated the most aggresive course of disease. It was found that a more pronounced tumor response to combination chemotherapy can be expected in young patients, pre-menopausal, high ECOG status. The presence of neutropenia has a significantly positive impact on the results of treatment of patients with metastatic breast cancer.

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA: a cancer journal for clinicians. 2013; 63(11):1.
  2. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Annals of Oncology. 1999; 10(4):413–419.
  3. Galea MH, Blamey RW, Elston CE. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22:207–219.
  4. Perevodchikova N.I., Stenina M.B. [Guide-lines for chemotherapy of neoplastic diseases]. Moscow: Practice; 2014. 238 p. Russian.
  5. Sun J, Wei W. Associations and indications of Ki-67 expression with clinicopathological param-eters and molecular subtypes in invasive breast cancer: A population-based study. Oncol Lett. 2015; 10(3):1741-1748.
  6. Prat A, Pineda E, Adamo B. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 2015. 24(2):S26-S35.
  7. Zhou W, Jirström K, Amini RM. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer. 2013; 13:512.
  8. Engstrоm MJ, Opdahl S, Hagen AI. Molecu-lar subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Preclinical Study Breast Cancer Research and Treatment. 2013; 140(3):463-473.
  9. Haque R, Ahmed SA, Inzhakova G. Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades. 2012; 21(10):1848-1855.
  10. Carvalho FM, Bacchi LM, Pincerato KM. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. 2014; 14:102.
  11. Shchepotin IB, Zotov AS, Lyubota RV. [Molecular subtypes of breast cancer determined by immunohistochemistry markers: clinical, biology aspects and prognosis]. Breast tumors. 2012; 8(4): 388. Russian.
  12. Maio MDi, Gridelli C, Gallo C. Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy? Nat Clin Pract Oncol. 2006; 3(3):114 - 115.
  13. Shitara K, Matsuo K, Oze I, Mizota A, Kondo C, Nomura M, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011; 68(2):301-7.
  14. Eskander RN, Tewari KS. Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian and cervical cancer: a systematic review. Journal of Hematological Malignancies. 2012; 2(3):63 – 73.
  15. Ozols R, Bundy B, Greer B, Fowler J, Clarke-Pearson D, Burger R, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21(17):3194-200.
  16. Goldhirsch F, Winer EP, Coates AS. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Ocol. 2013; 24:2206-2223.
  17. Petrov SV, Raykhlin NT. [Guide for immunohistochemical diagnostics of human tumors]. Kazan; 2004. 452p. Russian.
  18. Key M. Immunohistochemical Staining Methods. USA: Biomedical Services; 2006. 174р.
  19. Lakhani S, Ellis I, Schnitt S, authors. WHO Classification of Tumours of the Breast 4th. Lyon: IARC Press; 2012. 52 p.
  20. Moschetta M, Scardapane A, Lorusso V. Role of multidetector computed tomography in evaluating incidentally detected breast lesions. Tumori. 2015; 101(4):455-60.

Downloads

How to Cite

Phokhach, A. V., Elhajj, M. H., Bondarenko, I. N., Zavizion, V. F., & Hurtovyi, V. A. (2016). Prognostic value of clinical, laboratory and molecular predictors in the formation of personalized approaches to breast cancer treatment. Морфологія / Morphologia / Morfologìâ, 10(2), 53–60. https://doi.org/10.26641/1997-9665.2016.2.53-60

Issue

Vol. 10 No. 2 (2016)

Section

Статті

License

Copyright (c) 2018 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.